MSNBC - Biotie's Tozadenant (SYN115) Meets Primary and Multiple Secondary Endpoints in Phase 2b Study in Parkinson's Disease
Biotie today reported top-line data from a Phase 2b study evaluating its adenosine A2a antagonist tozadenant (SYN115) in Parkinson's disease (PD) patients experiencing levodopa related end of dose wearing off. The study met its primary endpoint of a statistically highly significant decrease in 'off' time vs. placebo, as well as demonstrating efficacy across multiple secondary endpoints. Full data from the study will be disclosed at upcoming medical conferences and in scientific publications. Dr. C Warren Olanow, Professor of Neurology and Neuroscience at Mount Sinai School of Medicine, stated, "This important study demonstrated that the A2a antagonist tozadenant reduced 'off' time in advanced PD patients. This agent, which does not act directly on the dopamine system, represents a new class of therapeutic agent that could be used to aid in the management of patients with this potentially disabling disorder."
- Dr. C. Warren Olanow, Professor Neurology, Neuroscience, Mount Sinai School of Medicine